Circulating microRNAs in Pancreatic Juice as Candidate Biomarkers of Pancreatic Cancer

Jin Wang
Massimo Raimondo
Sushovan Guha
Jinyun Chen
Lixia Diao

See next page for additional authors

Citation/Publisher Attribution
Wang J, Raimondo M, Guha S, Chen J, Diao L, Dong X, Wallace MB, Killary AM, Frazier ML, Woodward TA, Wang J, Sen S. Circulating microRNAs in Pancreatic Juice as Candidate Biomarkers of Pancreatic Cancer. J Cancer 2014; 5(8):696-705. doi:10.7150/jca.10094.
Available at: http://dx.doi.org/10.7150/jca.10094
Circulating microRNAs in Pancreatic Juice as Candidate Biomarkers of Pancreatic Cancer

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-No Derivative Works 3.0 License.

Authors
Jin Wang, Massimo Raimondo, Sushovan Guha, Jinyun Chen, Lixia Diao, Xiaoqun Dong, Michael B. Wallace, Ann M. Killary, Marsha L. Frazier, Timothy A. Woodward, Jing Wang, and Subrata Sen

This article is available at DigitalCommons@URI: https://digitalcommons.uri.edu/bps_facpubs/31
Circulating microRNAs in Pancreatic Juice as Candidate Biomarkers of Pancreatic Cancer

Jin Wang1*, Massimo Raimondo2*, Sushovan Guha3*, Jinyun Chen4, Lixia Diao5, Xiaoqun Dong6, Michael B. Wallace2, Ann M. Killary1,7, Marsha L. Frazier4,7, Timothy A. Woodward2, Jing Wang5, and Subrata Sen1,7

1. Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas; 2. Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, Florida; The University of Texas Medical School and Health Science Center at Houston, Texas; 3. Division of Gastroenterology, Hepatology, and Nutrition, The University of Texas Medical School and Health Science Center at Houston, Texas; 4. Epidemiology, Bioinformatics and Computational Biology, UT MD Anderson Cancer Center, Houston Texas; 5. Bioinformatics and Computational Biology, UT MD Anderson Cancer Center, Houston Texas; 6. Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, The University of Rhode Island, Kingston, Rhode Island; 7. Program in Human and Molecular Genetics, The University of Texas Graduate school of Biomedical Sciences, Houston, Texas.

* These authors contributed equally to this work.

Corresponding author: Subrata Sen, Ph.D. Department of Translational Molecular Pathology, Unit 2951. The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas-77030. Email: ssen@mdanderson.org.

© Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited.

Received: 2014.07.12; Accepted: 2014.08.21; Published: 2014.09.16

Abstract

Development of sensitive and specific biomarkers, preferably those circulating in body fluids is critical for early diagnosis of cancer. This study performed profiling of microRNAs (miRNAs) in exocrine pancreatic secretions (pancreatic juice) by microarray analysis utilizing pancreatic juice from 6 pancreatic ductal adenocarcinoma (PDAC) patients and two pooled samples from 6 non-pancreatic, non-healthy (NPNH) as controls. Differentially circulating miRNAs were subsequently validated in 88 pancreatic juice samples from 50 PDAC, 19 chronic pancreatitis (CP) patients and 19 NPNH controls. A marked difference in the profiles of four circulating miRNAs (miR-205, miR-210, miR-492, and miR-1427) was observed in pancreatic juice collected from patients with PDAC and those without pancreatic disease. Elevated levels of the four miRNAs together predicted PDAC with a specificity of 88% and sensitivity of 87%. Inclusion of serum CA19-9 level increased the sensitivity to 91% and the specificity to 100%. Enrichment of the four miRNAs in pancreatic juice was associated with decreased OS, as was the combination of miR-205 and miR-210. Higher contents of miR-205 and miR-210 were also associated with lymph node metastasis. Elevated levels of circulating miR-205, miR-210, miR-492, and miR-1247 in pancreatic juice are, therefore, promising candidate biomarkers of disease and poor prognosis in patients with PDAC.

Key words: miRNA; circulating; biomarker; pancreatic juice; pancreatic cancer.

Introduction

Pancreatic cancer is the fourth leading cause of cancer-related deaths in the United States, with a 5-year survival rate of about 6% (1). When the tumor is detected at an early stage, surgical resection and adjuvant chemotherapy or radiotherapy can increase the 5-year survival rate to 15-40% (2). Thus, screening strategies for detection of early stage cancer or precursor lesions in individuals at highest risk, as well as pancreatic cancer biomarker assays for biological fluids, are urgently needed to reduce the high mor-
bidity and mortality associated with this malignancy.

Exocrine pancreatic secretions, or pancreatic juice, collected from the second part of the duodenum after stimulation with intravenous synthetic human secretin using an upper endoscope (3-5) have been analyzed for molecular markers associated with pancreatic ductal adenocarcinoma (PDAC) (6, 7). Protein and gene expression profiles in the pancreatic juice of patients with PDAC have revealed novel protein markers and indicator genes that might be useful for PDAC diagnosis (8, 9). More recently, NGAL and MIC-1 in pancreatic juice were reported to be useful markers for diagnosing benign and malignant disease of the pancreas (10). However, since tumor-associated proteins may constitute only a minor fraction of the vast and dynamic range of proteins in blood plasma and other body fluids, proteomic-based strategies for identification of circulating cancer biomarkers have had limited success so far (11).

MicroRNAs (miRNAs) are a class of conserved small non-coding RNAs, which regulate gene expression via complementarity with the 3′-untranslated region of their target mRNAs, repressing translation and causing degradation of multiple target mRNAs (12). MicroRNAs have critical regulatory functions in cell development, proliferation, differentiation, apoptosis, and stress response. A number of studies in the past few years have established the regulatory roles of miRNAs in complex genetic networks underlying various cellular pathways (13). Aberrant expression of several miRNAs has been detected in PDAC and its precursor, pancreatic intraepithelial neoplasms (14). Varying levels of circulating miRNAs in body fluids have been associated with corresponding tumor-specific aberrant expression and proposed to represent novel biomarkers for detection and diagnosis of various cancers (15, 16). We have earlier demonstrated that miRNAs in the plasma of patients with pancreatic ductal adenocarcinoma (PDAC) may serve as novel blood-based biomarkers of disease (17). Serum and pancreatic cyst fluid levels of miR-21, miR-210 and miR-155 have been found elevated in patients with PDAC (18-21). Elevated serum level of miR-1290 has recently been reported to accurately distinguish patients with low stage pancreatic cancer from healthy and disease controls (22).

Altered levels of miRNAs in blood and body fluids can distinguish patients with cancer from healthy individuals (16, 17, 23). In view of a published report that relative expression levels of miR-21 and miR-155 in tissue and pancreatic juice from PDAC patients were significantly higher than those with chronic pancreatitis (24), it appears that unbiased profiling of circulating miRNAs in pancreatic juice may offer a viable approach for developing reliable biomarker assays for detecting PDAC. In this study, we performed microarray profiling of miRNAs in the pancreatic juice of patients with PDAC compared with those from individuals with chronic pancreatitis and non-pancreatic disease controls to investigate the utility of differentially circulating miRNAs as biomarkers for pancreatic cancer.

**Materials and Methods**

**Patients**

This prospective study was approved by the Mayo Clinic and M. D. Anderson Cancer Center Institutional Review Boards. Patients presenting at the Mayo Clinic with epigastric pain or discomfort warranting evaluation by endoscopic ultrasound-guided fine needle aspiration and later diagnosed with chronic pancreatitis (CP), pancreatic cancer or no pancreatic disease (non-pancreatic, non-healthy [NPNH] controls) were enrolled. Pancreatic juice and serum samples were collected. Sera were assayed for CA19-9 and the definitive final diagnosis was made. A multiphase, case-control study was designed to identify pancreatic juice miRNAs as potential markers for PDAC. In the initial biomarker identification stage, miRNA microarray profiling was performed on six pancreatic juice samples of PDAC patients and two pooled pancreatic juice samples from 6 NPNH controls to assay the circulating miRNA profiles. Validation of four differentially enriched miRNAs was then performed using qRT-PCR assay. All the pancreatic juice samples were separated randomly into training set (6 PDAC and 6 NPNH controls) and validation set (44 PDAC, 19 CP and 13 NPNH controls) prior to analysis from a total of 88 patients enrolled in the study as described previously (10).

**Collection of Secretin-Stimulated Exocrine Pancreatic Secretions (Pancreatic Juice)**

All patients underwent upper endoscopic intubation after an overnight fast. Patients were moderately sedated with midazolam and meperidine before the procedure. Synthetic human secretin (ChiRhoStim; ChiRhoClin Inc, Burtonsville, MD) at a dose of 0.2 μg/kg (or a total dose of 16 μg) was administered intravenously for 1 minute immediately before endoscopic intubation. Gastric fluid was aspirated before intubation of the pylorus to minimize contamination. With the endoscope positioned in the second portion of the duodenum, opposite the papilla of Vater (without cannulation), a 2.3-mm plastic aspiration catheter (Hobbs Medical, Stafford Springs, CT) was passed through the biopsy channel of the endoscope until it was visible on the endoscopic monitor screen. Pancreatic juice exiting the papilla was then suctioned.
through the catheter for 10 minutes into a dry 20-mL tube attached to the proximal end of the catheter. On average, 5-8 mL of fluid was collected from each patient. The collected fluid was immediately aliquoted into 2-mL vials, snap-frozen in liquid nitrogen, and stored at -80°C until assays for miRNA microarrays and real-time polymerase chain reaction were performed. A pan-protease inhibitor cocktail pill (Roche Diagnostic Corporation, Indianapolis, IN) was added to the collected pancreatic juice to inhibit proteolytic degradation.

**Determination of Final Diagnosis**

Three gastroenterologists (Massimo Raimondo, Michael B. Wallace, and Timothy A. Woodward), who were blinded to the results of the miRNA assays, determined the final diagnosis of the patients on the basis of clinical history and laboratory, radiologic (computed tomography or magnetic resonance imaging), or endoscopic (endoscopic ultrasound or endoscopic retrograde cholangiopancreatographic) findings (chronic pancreatitis) and cytologic or histologic findings (for those with pancreatic ductal adenocarcinoma). Patients with no prior history of pancreatic disease and who had normal pancreatic test results (ultrasound, cholangiopancreatography, computed tomography, or magnetic resonance imaging) were deemed to have normal pancreata and thus considered to be non-pancreatic, non-healthy (NPNH) controls.

**CA19-9 Measurement**

Concentrations of CA19-9 in the pancreatic juice and serum of patients were measured, as described previously (10). Briefly, CA19-9 antigen concentration was determined using a solid-phase radioimmunoassay (Centocor, Malvern, PA), according to the manufacturer’s instructions. Quantities of CA19-9 were expressed in arbitrary units (U/mL) with 1 unit of activity corresponding to approximately 0.8 ng of purified antigenic protein for CA19-9.

**miRNA Extraction and Purification**

Pancreatic juice was cleared through centrifugation at 1,300 × g at 4°C for 10 minutes and stored at -80°C. Total RNA was extracted and purified from all pancreatic juice samples. For the purpose, cleared pancreatic juice was mixed with Trizol LS (1:3 ratio; Life Technologies, Grand Island, NY), and after phase separation by centrifugation, the aqueous phase was extracted once with phenol/chloroform and added to ethanol before being applied directly to a mirVana miRNA column (Ambion, Austin, TX) according to the manufacturer’s instructions. The concentration of RNA samples was quantified using NanoDrop 2000 (NanoDrop, Wilmington, DE). The total amount of RNA extracted from 500 µL of pancreatic juice ranged from 0.21 to 18.90 µg (mean, 1.34 µg).

**miRNA Microarray Labeling, Hybridization, and Data Analysis**

The G4470A Agilent human miRNA microarray (Agilent Technologies, Santa Clara, CA) was used to profile miRNA. RNA labeling and hybridization were performed using the Agilent miRNA labeling reagent and hybridization kit according to the manufacturer’s protocol. Samples containing 100 ng of RNA were labeled with pCp-Cy3 using T4 RNA ligase (Ambion) and hybridized to microarrays. Microarrays were scanned using an Agilent microarray scanner, data were extracted, and array quality control was performed using Agilent Feature Extraction software. The AgiMicroRna package was used to process Agilent miRNA array data. In addition, hierarchical clustering was performed using Pearson correlation metrics with Ward’s linkage.

**Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) Analysis**

Taqman miRNA assays (Applied Biosystems, Foster City, CA) were used to perform expression profiling of the miRNAs of interest. RNA was pretreated with DNase (Invitrogen). Ten ng of DNase-treated RNA from each sample of pancreatic juice was used for each assay. Assays were performed in 15-µL reactions containing the reverse transcription mixture and Taqman primer mix. miRNA expression levels were quantified using the ViiA™ 7 Real-Time PCR System (Life Technologies). Relative expression of the mature miRNAs in terms of fold change in the test samples (PDAC or CP) compared with the non-pancreatic, non-healthy (NPNH) controls was calculated using the comparative CT (2^(-ΔΔCT)) method, using RNU6B as the endogenous control to normalize the data, where CT (cycle threshold) is defined as the number of cycles required for the FAM signal to cross the threshold in real-time PCR. ΔCT was calculated by subtracting the CT values of RNU6B from the CT values of the miRNA of interest. ΔΔCT was then calculated by subtracting the mean ΔCT of NPNH controls from the ΔCT of test samples (PDAC or CP).

**Locked Nucleic Acid In Situ Hybridization (LNA-ISH)**

For analyzing miRNA expression formalin-fixed, paraffin-embedded tumor tissue slides were toasted, de-waxed in xylene, and rehydrated through an ethanol dilution series. Tissue sections were digested with 15 µg/mL proteinase K and then treated with 3% hydrogen peroxide. Tissue sections were then subjected to prehybridization solution at 50°C for 30
minutes. The prehybridization solution was replaced with 50 µL of hybridization solution containing 10 pmol of the fluorescein isothiocyanate–labeled LNA probes for the miRNAs. Slides were blocked with 5% bovine serum albumin, incubated with anti-Fluorescein-HP conjugated antibodies, and subjected to the CSA II Biotin-free Tyramide Signal Amplification System Kit (DAKO, Carpenteria, CA) as described previously (25).

### Statistical Analysis

All clinicopathological variables and miRNA expression levels in pancreatic juice were analyzed using SPSS v19 (SPSS Inc, Chicago, IL). Unpaired t tests were used to compare pancreatic juice miRNA expression between groups and p values <0.05 were considered statistically significant. The relationship between miRNA expression and overall survival (OS) was analyzed using Cox proportional hazards regression models. Hazard ratios and 95% confidence intervals (CIs) were calculated, with adjustments made for sex, ethnicity, and other clinical factors that were significant predictors of OS in multivariate Cox regression models. Receiver operating characteristic (ROC) curves were constructed and the area under the curve (AUC) was calculated to evaluate the ability of each individual miRNA and CA19-9 either individually or in combination to detect pancreatic cancer. OS curves were estimated using the Kaplan-Meier method. The median expression level of each miRNA was used as the cutoff point in Kaplan-Meier survival analysis.

### Results

#### Patient Characteristics

Among the 88 patients enrolled in the study (training and validation sets), 19 were NPNH controls, 19 were diagnosed with CP, and 50 were diagnosed with PDAC. Patient demographic and clinicopathologic information is presented in Table 1. Among the 50 patients with PDAC, univariate analysis by SPSS showed that OS did not differ by age, sex, smoking and alcohol history, diabetes mellitus, CA19-9 findings, or lymph node involvement. The median OS duration of the 50 patients with PDAC was 7.90 months (95% CI, 4.17-41.09 months). However, the median follow-up time was 12.43 months for the patients who were still alive at the time of analysis. Well to moderate tumor differentiation was associated with increased OS duration (P=0.005).

### Pancreatic Juice miRNA Profiles of Patients with PDAC

The pancreatic juice miRNA microarray profiles of 6 patients with PDAC were compared with those of pooled samples from 6 NPNH controls. Hierarchical clustering of miRNA expression using the Pearson correlation distance metric and Ward’s linkage revealed clusters of patients with PDAC and NPNH controls after Robust Multi-Array Average (RMA) normalization (Fig. 1A). Levels of 49 miRNAs differed by at least 1.5-fold in the pancreatic juice of patients with PDAC compared with those of pooled samples from 6 NPNH controls.

**Table 1. Characteristics of the Study Population.**

| Characteristic | NPNH (n = 19) | CP (n = 19) | PDAC (n = 50) | No. of patients | No. of death | MST (months) | P value |
|---------------|---------------|-------------|---------------|----------------|-------------|-------------|---------|
| Age, years    |               |             |               |                |             |             |         |
| <60           | 9             | 8           | 12            | 7              | 10.73       |             | 0.188   |
| 61-70         | 6             | 5           | 18            | 15             | 8.70        |             |         |
| >70           | 4             | 6           | 20            | 13             | 4.37        |             |         |
| Sex           |               |             |               |                |             |             |         |
| Male          | 5             | 11          | 30            | 22             | 5.70        |             | 0.109   |
| Female        | 14            | 8           | 20            | 13             | 10.73       |             |         |
| Ethnicity     |               |             |               |                |             |             |         |
| White         | 16            | 17          | 48            | 34             | 8.00        |             | 0.047   |
| Black         | 2             | 1           | 2             | 1              | 2.07        |             |         |
| Hispanic      | 1             | 0           | 0             |                |             |             |         |
| Asian         | 0             | 1           | 0             |                |             |             |         |
| Smoking history* |         |             |               |                |             |             |         |
| Current       | 2             | 7           | 9             | 6              | 5.63        |             | 0.347   |
| Former        | 6             | 6           | 15            | 8              | 8.70        |             |         |
| Never         | 11            | 6           | 25            | 21             | 5.20        |             |         |
| History of alcohol use* | |             |               |                |             |             |         |
| Current       | 9             | 9           | 24            | 14             | 6.77        |             | 0.696   |
| Former        | 5             | 5           | 8             | 7              | 8.70        |             |         |
| Never         | 5             | 5           | 17            | 14             | 10.27       |             |         |
| Diabetes mellitus* | |             |               |                |             |             |         |
| Yes           | 3             | 5           | 10            | 7              | 3.93        |             | 0.451   |
| No            | 16            | 14          | 39            | 28             | 8.70        |             |         |
| CA19-9, U/mL  |               |             |               |                |             |             |         |
| <50           | 9             | 6           | 6             | 3              | 9.77        |             | 0.404   |
| 51-500        | 1             | 1           | 4             | 2              | 2.07        |             |         |
| 501-1500      | 3             | 4           | 5             | 4              | 2.33        |             |         |
| >1500         | 6             | 8           | 35            | 26             | 7.90        |             |         |
| Lymph node*   |               |             |               |                |             |             |         |
| 0             | 19            | 19          | 35            | 26             | 8.00        |             | 0.290   |
| 1             | 0             | 0           | 13            | 9              | 6.77        |             |         |
| Tumor differ-  |               |             |               |                |             |             |         |
| entiation       |             |             |               |                |             |             | 0.005   |
| Well to moderate | -           | -           | 9             | 5              | 18.33       |             |         |
| Poor or not available | -   | -           | 40            | 30             | 5.63        |             |         |

*Smoking history, history of alcohol use, diabetes status and tumor differentiation were not available for 1 patient with PDAC. *Lymph node was not available for 2 patient with PDAC.
files were grouped together (Fig. 1B). Multiple miRNAs with elevated profiles in the pancreatic juice, including miR-205 and miR-210, which are known to be overexpressed in PDAC tissue (26, 27), were found to segregate into distinct clusters in the dendrogram generated. We selected miR-492 and miR-1247, the top two miRNAs in the same cluster as miR-205 and miR-210, which have not been previously reported in PDAC, for validation as novel candidate biomarkers circulating at elevated levels in the pancreatic juice of patients with PDAC.

**Quantitative Real-Time Polymerase Chain Reaction (qRT-PCR) Analysis of Candidate miRNAs**

To validate the differential enrichment of four candidate miRNA biomarkers in pancreatic juice, identified on expression microarrays, we used qRT-PCR assay for 4 miRNAs (miR-205, miR-210, miR-492, and miR-1247) in individual pancreatic juice samples (training set). The relative abundance of four miRNAs, normalized to the level of RNU6B, significantly varied in pancreatic juice samples from patients with PDAC and NPNH. The levels of four miRNAs were further assayed in a larger cohort consisting of an independent set of pancreatic juice samples (validation set). The p values revealed that the levels of these miRNAs showed statistically significant differences among patients in these three groups (PDAC, CP and NPNH; miR-205, \( P = 0.04 \); miR-210, \( P = 1.90E-05 \); miR-492, \( P = 0.005 \); miR-1247, \( P = 0.04 \); Fig. 2A and Table 2). The mean fold changes of miRNAs and the p values reflected segregation of PDAC, CP, and NPNH samples in terms of varying miRNA levels, with the levels relatively high in PDAC, low in controls and intermediate in CP although the difference between PDAC and CP were not significant.

**Figure 1. Hierarchical clustering analysis of microRNA microarray expression profile.** (A) Clusters of patients with pancreatic ductal adenocarcinoma (PDAC) and non-pancreatic, non-healthy controls (NPNH). (B) Hierarchical clustering of microRNA expression in PDAC pancreatic juice samples with similar miRNA profiles were grouped together, which showed that miR-492, miR-1247, miR-205 and miR-210 were in the same cluster.
Figure 2. Quantitative real-time polymerase chain reaction (qRT-PCR) and Locked nucleic acid in situ hybridization (LNA-ISH) analysis of expression levels of microRNAs. (A) qRT-PCR analysis of relative expression levels of 4 microRNAs (miR-205, miR-210, miR-492, and miR-1247) in pancreatic juice samples from patients with pancreatic ductal adenocarcinoma (PDAC), patients with chronic pancreatitis (CP), and non-pancreatic, non-healthy (NPNH) controls. The relative abundance of four miRNAs, normalized to the level of RNU6B, significantly varied in pancreatic juice samples from patients with PDAC, CP and NPNH. (B) LNA-ISH-IHC images showing miR-492 expression in 3 (J101, J16, J39) pancreatic ductal adenocarcinoma tissue samples (magnification ×100). (C) The graph shows qRT-PCR results for miR-492 in pancreatic juice samples from the same patients.

Table 2. MicroRNA (miRNA) expression in samples of pancreatic juice from patients with pancreatic ductal adenocarcinoma (PDAC); Chronic pancreatitis (CP); Non-pancreatic, non-healthy controls (NPNH).

| miRNA expression | NPNH samples (n = 19, no. (%)) | CP samples (n = 19, no. (%)) | PDAC samples (n = 50, no. (%)) | P value |
|------------------|---------------------------------|------------------------------|--------------------------------|---------|
| miR-205 Low      | 14 (74)                         | 10 (53)                      | 20 (40)                        | 0.04    |
| miR-205 High     | 5 (26)                          | 9 (47)                       | 30 (60)                        |         |
| miR-210 Low      | 18 (95)                         | 10 (53)                      | 16 (32)                        | 1.90E-05|
| miR-210 High     | 1 (5)                           | 9 (47)                       | 34 (68)                        |         |
| miR-492 Low      | 16 (84)                         | 10 (53)                      | 20 (40)                        | 0.005   |
| miR-492 High     | 3 (16)                          | 9 (47)                       | 30 (60)                        |         |
| miR-1247 Low     | 13 (76)                         | 9 (47)                       | 20 (41)                        | 0.04    |
| miR-1247 High    | 4 (24)                          | 10 (53)                      | 29 (59)                        | 8.31E-04|
| miR-205/miR-210  | 19 (100)                        | 13 (68)                      | 26 (52)                        |         |
| P value          |                                 |                              |                                |         |

The relative increase in the levels of the candidate miRNAs in pancreatic juice samples from patients with PDAC was significantly higher than in samples from NPNH controls (miR-205, P = 0.009; miR-210, P = 0.010; miR-492, P = 0.003; miR-1247, P = 0.041; Additional File 1: Supplementary Table S2). These results were in good agreement with microarray and training set results. Levels of the candidate miRNAs were higher in the CP samples than in the NPNH samples, although the difference was statistically significant for only miR-492. Levels of miR-205, miR-210, and miR-1247 did not differ between the CP samples and the NPNH samples. These miRNAs were significantly elevated in PDAC samples compared with NPNH samples but not compared with the CP samples.

Expression of miRNAs in PDAC Tumor Samples

To investigate whether varying levels of miRNAs detected in the pancreatic juice of patients with PDAC reflected differential expression of the miRNAs in pancreatic tumor tissues, we performed LNA-ISH with the miRNA probes on a limited set of 12 available tumor tissue samples. miRNAs detected by LNA-ISH in the tumor tissues (Fig. 2B) were consistent with those detected in the corresponding pancreatic juice samples (Fig. 2C).

To estimate miRNA-492 and miRNA-1247 differential expression in PDAC, qRT-PCR analysis of miRNA expression was also undertaken in 34 paired samples of PDAC tissue and adjacent normal tissue. Twenty PDAC tumor samples (59%) showed increased expression of miR-492, and only 13 samples (38%) showed increased expression of miR-1247 (data not shown).
Pancreatic Juice miRNA Profiles as Biomarkers of PDAC

The ability of the 4 miRNAs to differentiate PDAC pancreatic juice samples from NPNH pancreatic juice samples was assessed using ROC curves, which indicated that the 4 miRNAs are candidate biomarker of PDAC (miR-205 AUC = 0.68; miR-210 AUC = 0.84; miR-492 AUC = 0.80; miR-1247 AUC = 0.63). For all 4 miRNAs combined, the AUC was 0.92, documenting that the altered levels of the 4 miRNAs in pancreatic juice can differentiate patients with PDAC from NPNH controls. When serum expression of CA19-9 was considered along with the 4 miRNAs, the AUC was 0.99, which was significantly improved compared with both CA19-9 alone (AUC = 0.89) and the combination of the 4 miRNAs without CA19-9 (Fig. 3A and Additional File 1: Supplementary Table S3).

ROC curves helped determine the sensitivities and specificities of the miRNAs at various cutoff values (Supplementary Table S3). Using the optimal cutoff points, sensitivity and specificity were 64% and 74%, respectively, for miR-205; 76% and 95% for miR-210; 73% and 82% for miR-492; and 53% and 88% for miR-1247. The sensitivity and specificity for the 4 miRNAs combined were 87% and 88%, respectively. Finally, the combination of the 4 miRNAs plus CA19-9 had a sensitivity of 91% and a specificity of 100%, which was significantly improved than CA19-9 alone (77% sensitivity, 93% specificity).

Pancreatic Juice miRNAs as Biomarkers for PDAC Prognosis, Tumor Differentiation, and Lymph Node Metastasis

We performed Kaplan-Meier analyses to assess the relationship between pancreatic juice miRNA levels and clinical outcome, using the median expression level as a cutoff (at or above the median = high expression; below the median = low expression), in 36 PDAC patients for whom all the clinical data were available. Multivariate Cox regression models for individual miRNAs and combinations of miRNAs are shown in Table 3. Patients with low levels of miR-205 or miR-210 (individually) had longer OS durations than patients with high levels of these miRNAs, but the difference was not statistically significant (miR-205 log-rank \( P = 0.166 \); miR-210 log-rank \( P = 0.211 \)). However, we found that elevated levels of all 4 miRNAs was associated with shorter OS (log-rank \( P = 0.050 \)), as was high expression of both miR-205 and miR-210 together (log-rank \( P = 0.029 \)). Patients with low levels of both miR-205 and miR-210 tended to have longer OS durations than did patients with high levels of both miR-205 and miR-210 (Fig. 3B).

Patients with low levels of both miR-205 and miR-210 appeared less likely to have lymph node metastasis than patients with high levels of both miR-205 and miR-210 (Additional File 1: Supplementary Table S4). Patients with low levels of miR-205 also tended to have well to moderately differentiated tumors (\( P = 0.001 \)) (Additional File 1: Supplementary Table S4).

Figure 3. Receiver operating characteristic curves (ROC) and Kaplan-Meier plots showing association of pancreatic juice miRNA profiles in PDAC patients and their clinical outcome. (A) Receiver operating characteristic curves showing expression levels of individual microRNAs (miR-205, miR-210, miR-492, and miR-1247), CA19-9, and a combination. (B) Kaplan-Meier overall survival curves for patients with pancreatic ductal adenocarcinoma with high levels of both miR-205 and miR-210 at or above the median (shown in green); either miR-205 or miR-210, or neither upregulated in pancreatic juice samples (shown in blue). The curves were compared using univariate (log-rank) analysis.
Table 3. Median overall survival time (MST) of pancreatic ductal adenocarcinoma (PDAC) patients with high and low levels of circulating miRNAs in pancreatic juice.

| miRNA expression | No. of patients | No. of deaths | MST, months | Log-rank value | P value | HR (95% CI) |
|------------------|----------------|---------------|-------------|----------------|---------|------------|
| miR-205          |                |               |             |                |         |            |
| Low              | 15             | 13            | 12.40       | 0.166          | 1.46(0.66-3.12) | 0.347     |
| High             | 20             | 20            | 5.63        |                |         |            |
| miR-210          |                |               |             |                |         |            |
| Low              | 11             | 9             | 11.33       | 0.211          | 1.78(0.66-4.80) | 0.254     |
| High             | 25             | 24            | 6.77        |                |         |            |
| miR-492          |                |               |             |                |         |            |
| Low              | 17             | 15            | 7.90        | 0.678          | 0.82(0.36-1.83) | 0.620     |
| High             | 19             | 18            | 8.70        |                |         |            |
| miR-1247         |                |               |             |                |         |            |
| Low              | 14             | 14            | 6.77        | 0.586          | 1.47(0.67-3.23) | 0.334     |
| High             | 21             | 18            | 7.90        |                |         |            |
| miR-205/miR-210  |                |               |             |                |         |            |
| Low              | 32             | 29            | 8.70        |                |         |            |
| High             | 4              | 4             | 3.77        | 0.050          | 2.87(0.93-8.87) | 0.067     |
| miR-492/miR-1247 |                |               |             |                |         |            |
| Low              | 18             | 15            | 11.33       |                |         |            |
| High             | 18             | 18            | 9.39        | 0.029          | 2.14(1.06-4.29) | 0.030     |

Discussion

Elevated levels of microRNAs have been detected in precursor lesions of pancreatic cancer and were also associated with poorer survival of pancreatic cancer patients (26, 27). Our results indicate that miR-205, miR-210, miR-492, and miR-1247 in pancreatic juice are candidate biomarkers of PDAC, which perform even better when combined with serum CA19-9 levels. We also found that expression of these 4 miRNAs is associated with decreased OS in patients with PDAC. In addition, elevated amount of miR-205 and miR-210 was associated with lymph node metastasis, and expression of miR-205 was associated with poorly differentiated tumors, both indicators of worse prognosis. These findings suggest that pancreatic juice levels of miR-205, miR-210, miR-492, and miR-1247, as a combined signature can predict the clinical outcome of patients with PDAC.

Microarray analyses identified 49 miRNAs as differentially enriched in the pancreatic juice of patients with PDAC compared with controls; of these, miR-200a, miR-200b, and miR-30b have also been found to be upregulated in PDAC cells and tumor tissue (28). In addition, high expression of miR-205 was found in head and neck cancer cell lines (29), squamous cell carcinoma cell lines (30), and cervical cancer cell lines (31), as well as in clinical samples of metastatic head and neck squamous cell carcinoma (32), cervical cancer (31), non-small cell lung cancer (33), and endometrial cancer (34). Expression of miR-205 in clinical prostate cancer samples was associated with prostate cancer progression (35) and invasive bladder cancers (36). Up-regulation of miR-205 was also found to precede phenotypic changes in ductal cells in a conditional KRAȘ (G12D) mouse model of pancreatic cancer (27).

Aberrant high expression of miR-210 has been detected in many tumors (26, 37-42). Elevated miR-210 has been implicated in tumor progression (43) and is associated with negative clinical outcomes (26, 41, 42). Interestingly, increased plasma miR-210 levels were associated with lymph node metastases and trastuzumab resistance in breast cancer patients (44). These findings are to some extent consistent with our current observation that high miR-205 and miR-210 levels in pancreatic juice correlates with decreased OS, poorly differentiated tumors, and lymph node metastasis. These observations make a compelling case for miR-205 and miR-210 in pancreatic juice as informative biomarkers for PDAC.

A recent study has reported miR-1247 to be down-regulated in pancreatic cancer correlating with tumor grade and shorter overall survival of the patients (45). miR-492 has also been shown to potentially play an important role in the progression of malignant embryonal liver tumors (46). Although our study did not reveal significant differences in the levels of these miRNAs between CP and PDAC, it is plausible that this was due to relatively small sample size and thus lack of enough statistical power in the current study. However, in view of these miRNAs discriminating PDAC from NPNH controls with reasonably high sensitivity and specificity as well as showing significant correlation with decreased OS and lymph node metastasis, it is important that the miRNA signature be investigated in a larger patient population in the future. The current finding of the four miRNAs signature in pancreatic juice as a biomarker panel of pancreatic cancer suggest that these miRNAs are involved in critical cancer relevant genetic networks deregulated in PDAC.

Collection of pancreatic juice is a minimally invasive procedure which can easily detect circulating or secreted miRNAs as concentrations of miRNAs are higher than in blood (serum or plasma). This is important as circulating miRNAs in blood can potentially decrease over time whereas they can be still detectable in pancreatic juice. For detection of early PDAC, this procedure will be preferable as concentrations of miRNAs will be higher in pancreatic juice than in blood. Moreover, our technique can be used as
part of routine diagnostic procedure to establish diagnosis/staging of PDAC and does not involve cannulation of pancreatic duct to collect pancreatic juice.

Finally, we recognize that the procedure is expensive if secretin is used and more invasive unlike detecting miRNAs in blood. The collection and storage procedures need to be standardized for a broader applicability of this technique. It is important to have stringent quality control standards for collection of pancreatic juice and pancreatic juice miRNAs expression analysis besides ensuring that sample size is adequate for selecting the most informative candidate biomarker miRNAs capable of discriminating patients with pancreatic cancer, pancreatitis versus no pancreatic disease.

In summary, our study demonstrates that miRNAs in exocrine pancreatic secretions are promising biomarkers of PDAC. Further comprehensive molecular and functional characterizations of miRNAs circulating at altered levels in pancreatic juice are warranted to elucidate the role of these miRNAs in pancreatic carcinogenesis and validate them in larger sample cohorts as biomarker panels for detection, prognostics as well as response to therapy for this highly lethal malignancy.

Abbreviations
AUC, area under the curve; CA19-9, carbohydrate antigen 19-9; CP, chronic pancreatitis; LNA-ISH, microRNA; NPNH, non-pancreatic, non-healthy; OS, locked nucleic acid in situ hybridization; miRNA, competing interests

Acknowledgement
The biomarker discovery work in Subrata Sen’s laboratory is supported by a grant (U01 CA111302) from the Early Detection Research Network of the National Cancer Institute/National Institutes of Health, USA. The University of Texas MD Anderson Cancer Center is supported in part by a Cancer Center Support Grant (CA016672) from the National Institutes of Health.

Competing Interests
The authors have declared that no competing interest exists.

References
1. Jemal A, Siegel R, Xu J, et al. Cancer statistics. 2010. CA Cancer J Clin. 2010, 60(5):277-300.
2. Yeo CJ, Cameron JL, Lillemoe KD, et al. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg, 1995, 221(6):721-731.
3. Ohachida K, Mizumoto K, Fujita H, et al. Sonic hedgehog is an early developmental marker of intraductal papillary mucinous neoplasms: clinical implications of miRNA levels in pancreatic juice. J Pathol. 2006, 201(3):42-48.
4. Noh KW, Pungapong S, Wallace MB, et al. Do cytokine concentrations in pancreatic juice predict the presence of pancreatic diseases? Clin Gastroenterol Hepatol. 2006, 4(6):782-789.
5. Raimondo M, Imoto M, DiMagno EP. Rapid endoscopic secretin stimulation test and discrimination of chronic pancreatitis and pancreatic cancer from disease controls. Clin Gastroenterol Hepatol. 2003, 1(5):397-403.
6. Ohachida K, Mizumoto K, Yu J, et al. S100A6 is increased in a stepwise manner during pancreatic carcinogenesis: clinical value of expression analysis in 98 pancreatic juice samples. Cancer Epidemiol Biomarkers Prev. 2007, 16(suppl 4):649-654.
7. Nakashima A, Murakami Y, Uemura K, et al. Usefulness of human telomerase reverse transcriptase in pancreatic juice as a biomarker of pancreatic malignancy. Pancreas. 2009, 38(5):527-533.
8. Tian M, Cui YZ, Song GH, et al. Proteomic analysis identifies MMP-9, DJ-1 and A1BG as overexpressed proteins in pancreatic juice from pancreatic ductal adenocarcinoma patients. BMC Cancer. 2008, 8:241.
9. Oliveira-Cunha M, Byers RJ, Siriwardena AK, Polyl(A)-RT-PCR measurement of diagnostic genes in pancreatic juice in pancreatic cancer. Br J Cancer. 2011, 104(3):514-519.
10. Kuwata S, Baine MJ, Guha S, et al. Neutrophil gelatinase-associated lipocalin, macrophage inhibitory cytokine 1, and carbohydrate antigen 19-9 in pancreatic juice: pathobiologic implications in diagnosing benign and malignant disease of the pancreas. Pancreas. 2013, 42(3):494-501.
11. Hanashi SM, Fitter SI, Faca VM. Mining the plasma proteome for cancer biomarkers. Nature. 2008, 452(7187):571-579.
12. Macfarlane LA, Murphy PR. MicroRNA: Biogenesis, Function and Role in Cancer. Curr Genomics. 2010, 11(7):537-561.
13. Wang J, Sen S. MicroRNA functional network in pancreatic cancer: from biology to biomarkers of disease. J Biosci. 2011, 36(3):481-491.
14. Xue Y, Abou Tayoun AN, et al. MicroRNAs as diagnostic markers for pancreatic ductal adenocarcinoma and its precursor, pancreatic intraepithelial neoplasms. Cancer Genet. 2013, 206(6):217-221.
15. Thosani N, Dasari CS, Bhutani MS, et al. Molecular pathogenesis of intraductal papillary mucinous neoplasms of the pancreas. Pancreas. 2010, 39(9):1129-1133.
16. Chen X, Ba Y, Ma L, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008, 18(10):997-1006.
17. Wang J, Chen J, Chang P, et al. MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. Cancer Prev Res (Phila). 2009, 2(9):807-815.
18. Ho AS, Huang X, Cao H, et al. Circulating miR-210 as a Novel Hypoxia Marker in Pancreatic Cancer. Transl Oncol. 2010, 3(2):109-113.
19. Liu J, Gao J, Du Y, et al. Combination of plasma microRNAs with serum CA19-9 for early detection of pancreatic cancer. Int J Cancer. 2012, 131(3):683-691.
20. Ryu JK, Matthaei H, Dal Molin M, et al. Elevated microRNA miR-21 levels in pancreatic cyst fluid are predictive of mucinous precursor lesions of ductal adenocarcinoma. Pancreatology. 2011, 11(3):343-350.
21. Kong X, Du Y, Wang G, et al. Detection of differentially expressed microRNAs in serum of pancreatic ductal adenocarcinoma patients: miR-196a could be a potential marker for poor prognosis. Dig Dis Sci. 2011, 56(2):602-609.
22. Li A, Yu J, Kim H, et al. MicroRNA array analysis finds elevated serum miR-1290 accurately distinguishes patients with low-stage pancreatic cancer from healthy and disease controls. Clin Cancer Res. 2013, 19(13):3600-3610.
23. Mitchell PS, Parkin RK, Kroh EM, et al. Circulating microRNAs as stable blood-based markers for cancer detection. P Natl Acad Sci USA. 2008, 105(30):10513-10518.
24. Sadakari Y, Ohtsuka T, Ohuchida K, et al. MicroRNA expression analyses in preoperative pancreatic juice samples of pancreatic ductal adenocarcinoma. JOP. 2010, 11(6):587-592.
25. Sempere LF, Preis M, Yezezki T, et al. Fluorescence-based cdetection with protein markers reveals distinct cellular compartments for altered MicroRNA expression in solid tumors. Clin Cancer Res. 2010, 16(16):4246-4255.
26. Grether T, Grochola LF, Udelnow A, et al. Elevated expression of microRNA-155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. Int J Cancer. 2010, 126(1):73-80.
27. du Rieu MC, Torrisiani J, Selves J, et al. MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. Clin Chem. 2010, 56(4):603-612.
28. Kent OA, Mullendore M, Wentzel EA, et al. A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells. Cancer Biol Ther. 2009, 8(21):2013-2021.
29. Jiang JM, Lee EJ, Gusey Y, et al. Real-time expression profiling of microRNA precursors in human cancer cell lines. Nucleic Acids Res. 2005, 33(17):5394-5403.

Additional File 1: Supplementary Tables S1-S4.
http://www.jcancer.org/v05p0696s1.pdf
30. Yu J, Ryan DG, Getsios S, et al. MicroRNA-184 antagonizes microRNA-205 to maintain SHIP2 levels in epithelia. P Natl Acad Sci USA. 2008, 105(49):19300-19305.
31. Wang X, Tang S, Le SY, et al. Aberrant expression of oncogenic and tumor-suppressive microRNAs in cervical cancer is required for cancer cell growth. PloS One. 2008, 3(7):e2557.
32. Fletcher AM, Heaford AC, Trask DK. Detection of Metastatic Head and Neck Squamous Cell Carcinoma Using the Relative Expression of Tissue-Specific Mir-205. Transl Oncol. 2008, 1(4):202-209.
33. Markou A, Tsaroucha EG, Kaklamanis L, et al. Prognostic value of mature microRNA-21 and microRNA-205 overexpression in non-small cell lung cancer by quantitative real-time RT-PCR. Clin Chem. 2008, 54(10):1696-1704.
34. Karayiannis M, Zhang C, Liang SR, et al. Prognostic Significance of miR-205 in Endometrial Cancer. PloS One. 2012, 7(4).
35. Schaefer A, Jung M, Mollenkopf HJ, et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer. 2010, 126(5):1166-1176.
36. Wszolek MF, Rieger-Christ KM, Kenney PA, et al. A MicroRNA expression profile defining the invasive bladder tumor phenotype. Urol Oncol. 2011, 29(6):794-801.
37. Giannakakis A, Sandaltzopoulos R, Greshock J, et al. miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther. 2008, 7(2):255-264.
38. Porkka KP, Pfeiffer MJ, Waltering KK, et al. MicroRNA expression profiling in prostate cancer. Cancer Res. 2007, 67(13):6130-6135.
39. Lawrie CH, Gil S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma. Br J Haematol. 2008, 141(5):672-675.
40. Iorio MV, Ferracin M, Liu CG, et al. MicroRNA gene expression deregulation in human breast cancer. Cancer Res. 2005, 65(16):7065-7070.
41. Camps C, Buffa FM, Colella S, et al. hsa-miR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res. 2008, 14(5):1340-1348.
42. Gee HE, Camps C, Buffa FM, et al. hsa-miR-210 Is a Marker of Tumor Hypoxia and a Prognostic Factor in Head and Neck Cancer. Cancer. 2010, 116(9):2148-2158.
43. Chan YC, Banerjee J, Choi SY, et al. miR-210: The Master Hypoxamir. Microcirculation. 2012, 19(3):215-223.
44. Jung EJ, Santarpia L, Kim J, et al. Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer. 2012, 118(10):2603-2614.
45. Shi S, Lu Y, Qin Y, et al. miR-1247 is Correlated with Prognosis of Pancreatic Cancer and Inhibits Cell Proliferation by Targeting Neuropilins. Curr Mol Med. 2014, 14(5):327-327.
46. von Frowein J, Pagel P, Kappler R, et al. MicroRNA-492 is Processed from the Keratin 19 Gene and Up-Regulated in Metastatic Hepatoblastoma. Hepatology. 2011, 53(3):833-842.